Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Receivables: 2021

Historic Receivables for Nurix Therapeutics (NRIX) over the last 1 years, with Nov 2021 value amounting to $6.9 million.

  • Nurix Therapeutics' Receivables was N/A to $20.7 million in Q2 2025 from the same period last year, while for May 2025 it was $43.6 million, marking a year-over-year change of. This contributed to the annual value of $6.9 million for FY2021, which is N/A change from last year.
  • According to the latest figures from FY2021, Nurix Therapeutics' Receivables is $6.9 million.
  • Nurix Therapeutics' 5-year Receivables high stood at $6.9 million for FY2021, and its period low was $6.9 million during FY2021.
  • Its 1-year average for Receivables is $6.9 million, with a median of $6.9 million in 2021.